Science

Stephen V Liu: Results from the phase II study of zenocutuzumab in NRG1 fusion+ cancers

Stephen V Liu/X

Feb 8, 2025, 06:50

Stephen V Liu: Results from the phase II study of zenocutuzumab in NRG1 fusion+ cancers

Stephen V Liu, Associate Professor of Medicine at Georgetown University, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, shared a post on LinkedIn:

Results from the phase II study of zenocutuzumab in NRG1 fusion+ cancers now online in the New England Journal of Medicine.

Overall RR 30% with DOR 11.1m, PFS 6.8m, and a very favorable safety profile. NRG1+ lung cancers do not respond well to standard chemotherapy or immunotherapy. The fusions can be hard to find – RNA sequencing is the best way to identify them. Zenocutuzumab is now FDA approved for NRG1 positive lung cancer and pancreatic cancer.

Glad to finally have an approved option for this subset of cancers.

Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer

Authors: Alison M. Schram, et al.

Stephen V Liu: Results from the phase II study of zenocutuzumab in NRG1 fusion+ cancers

Alison M. Schram cancer fight against cancer Global awareness Global fight against cancer New England Journal of Medicine NRG1 fusion OncoDaily Oncology Stephen V Liu zenocutuzumab

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More